Laboratoire de Biochimie Générale et Enzymologie, CHU Pontchaillou, Rennes, France.
Clin Chem Lab Med. 2010;48(1):73-9. doi: 10.1515/CCLM.2010.012.
The Freelite system for nephelometric or turbidimetric measurement of serum free light chains (FLCs) has been available since 2001. It has been valuable for the management of patients with oligosecretory myeloma, light chain myeloma and AL amyloidosis. However, there are several limitations of the method. The goal of this study was to evaluate the analytical performance of the FLC assay.
Titrated controls and clinical serum specimens were used to determine precision and post-dilution recovery.
As reported elsewhere, we found that the assay had several limitations, including poor post-dilution linearity and overestimation by nephelometry.
These data demonstrate that the results of the FLC assay must be interpreted jointly by the clinician and the biologist, taking into account the individual patient's clinical and biological characteristics.
2001 年以来，已有用于血清游离轻链（FLC）比浊或散射测量的 Freelite 系统。它对于寡分泌型骨髓瘤、轻链型骨髓瘤和 AL 淀粉样变性患者的管理非常有价值。然而，该方法存在一些局限性。本研究的目的是评估 FLC 检测的分析性能。
使用滴定对照品和临床血清标本来确定精密度和稀释后回收率。
正如其他地方报道的，我们发现该检测存在一些局限性，包括稀释后线性不佳和散射法的高估。
这些数据表明，FLC 检测的结果必须由临床医生和生物学家共同解读，同时考虑到患者的个体临床和生物学特征。
